Supportive Care

Frontline Pola-R-CHP, CAR-T Second-Line Therapy Are Not Cost-Effective Choices For Patients With DLBCL

January 05, 2023

An economic analysis showed that neither polatuzumab vedotin nor CD19-directed CAR T-cell therapy are likely to be the most cost-effective for patients with diffuse large B-cell lymphoma based on their high costs and current long-term survival estimates.